Prescription digital therapeutics.

Software as medicine. Nutrition as active substance.

About us

Perfood is research-oriented digital therapeutics company. We develop innovative solutions to prevent and treat diseases by using personalized low-glycemic diet as a digital biomarker and „active ingredient“. Our approach has its roots in the Institute for Nutritional Medicine at the University of Lubeck, one of Germany’s premier medical schools.

glucose metabolism

The glucose metabolism has been linked to weight gain and systemic inflammation. Strong variation in glycemic responses have been associated with several diseases, such as Type 2 Diabetes, obesity, migraines, PCOS, psoriasis and many more. Generalized low-glycemic dietary interventions have shown short-term results but failed to deliver lasting effectiveness. 

At Perfood, we have developed a unique approach by giving personalized low-glycemic diet recommendations and embedding it into diseases-specific digital coaching programs. As a result, we observe lasting adherence and effectiveness. 


Certified medical device according to MDR risk class I

Use of glucose sensors from leading manufacturers that have been proven millions of times over

Perfood complies with the regulations of the EU DSGVO and ISO 27001

How does it work?

Our prescription digital therapeutics are reimbursed by German Statutory Health Insurance groups and many private insurance groups. Digital therapeutics may be prescribed as stand-alone therapy or in combination with conventional drugs. Our products all have features to track medication intake, symptoms and many other factors. Physicians may receive a summary report from patients that shows progression of disease and development of key markers in a clear format.

How much does it cost?

Digital therapeutics from Perfood are covered by all German Statutory Health Insurance groups under the Digital Care Act.

Digital therapeutics are listed as supportive care tool by health insurance groups. 

Want to learn more?

Our products follow a rigorous clinical evaluation process. Our studies create an opportunity to be among the first to benefit from our innovative digital therapeutics and to make a contribution in bringing them to underserved patient groups. We conduct studies at various study sites and complete remote accompanied by telemedical consultations. Want to learn more about our trials? Let’s have a chat.  

Stay up-to-date and check out and learn more about our products under development and commercially available.